lifestyle.realie.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Indivior Pharmaceuticals Inc.
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
March 31, 2026
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
March 17, 2026
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
March 12, 2026
Indivior Announces Proposed Convertible Senior Notes Offering
March 12, 2026
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
March 11, 2026
Indivior to Participate in Upcoming Investor Conferences
February 24, 2026
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
January 28, 2026
Indivior Announces Completion of Redomiciliation to the United States
January 26, 2026